Pharmacologic Therapy for
|
|
- Russell Wiggins
- 5 years ago
- Views:
Transcription
1 End-Stage Heart Disease Symposium Pharmacologic Therapy for Patients with Congestive Cardiomyopathy Richard A. Goldstein, M.D., and Desmond D. Levin, M.D. Treatment in congestive heartjailure is directed at improving cardiac output and decreasing preload and afterload without significantly increasing the oxygen requirements of the heart. This paper reviews the current approach to heart failure with inotropic and vasodilator drugs in patients with heartfailure. Texas Heart Instiute Journal 1987; 14: ) Key words: Cardiac output; cardiomyopathy, congestive; heart failure, congestive; inotropic agents; vasoconstrictor agents; vasodilator agents UNTIL THE 1970s, THERAPY of congestive heart failure consisted of digitalis for its inotropic effects and diuretics to reduce pulmonary and penpheral edema. In the 1970s, vasodilator drugs were used to treat heart failure by unloading the heart. Initially, this treatment was started very cautiously because of the fear that these drugs might lower arterial pressure by interfering with compensatory changes in vascular resistance that were necessary for maintenance of adequate perfusion. However, subsequent clinical studies have demonstrated that vasodilators improve cardiac performance, relieve pulmonary congestion, and reduce afterload while decreasing myocardial oxygen consumption. Recently there has been controversy on the use of inotropic drugs in the treatment of heart failure. One concern is the question of whether drugs that increase contractility might also accelerate death of the patient by increasing myocardial oxygen demand, and hence the work of the heart. In this article, recent developments in the medical treatment of congestive heart failure will be reviewed. Inotropic Drugs Digitalis Glycosides. Digitalis has been used by physicians for two hundred years, yet there is still concern about whether it has a significant beneficial effect in treating patients with congestive heart failure. A multicenter clinical trial sponsored by the National Institutes of Health is being planned to determine if digitalis significantly improves the functional status of the patient and his longevity. A new concem is the possibility that patients to whom digitalis is given following acute myocardial infarction are actually placed at higher risk of death. 1-3 The inotropic action of digitalis glycosides is due to inhibition of the Na-K ATPase pump. The consequent accumulation of extracellular sodium then stimulates the Na-Ca pump, which increases the availability ofcalcium to the contractile proteins. In clinical use in acute heart failure, From the Division of Cardiology, Departnent of Internal Medicine, School of Medicine, The University of Texas Health Science Center at Ho This paper has been adapted from a talk given at a symposium titled "Diagnosis and Treatment of End-Stage Heart Disease: Heart Transplantation and Assist Devices, 1987;' sponsored by the Texas Heart Institute and held February 5-7, 1987 at the Westin Galleria Hotel, Houston. Address for reprints: Richard A. Goldstein, M.D., Division of Cardiology, School of Medicine, Room 1.246, 6431 Fannin Street, Houston, JX Pharmacologic Therapy for Congestive Cardiomyopathy 341
2 digoxin increases cardiac output by 5-15%, without a predictable effect on either systemic vascular resistance or left-ventricular filling pressure.4 The onset of drug action does not occur for as long as two hours after administration, and, once administered, digoxin has a long half-life that precludes titration to achieve a particular clinical effect.5 Most cardiologists would agree that in the acute setting, digoxin's role is to treat supraventricular arrhythmias rather than to augment contractile function. In patients with chronic heart failure, the drug appears to be best suited for those with dilated hearts and an S3 gallop on examination.6-7 The duration of physical activity may not be significantly affected, although the National Institutes of Health SOLVD (Studies of Left Ventricular Dysfunction) trial undoubtedly will address this issue. While discussion of the side effects of digitalis glycosides is beyond the scope of this article, numerous reviews that detail its narrow therapeutic-to-toxic ratio5 are available to the interested reader. Inotropic Catecholamines. Inotropic catecholamines include epinephrine, norepineprine, isoproterenol, dopamine, and dobutamine. All of these agents increase contractility by stimulation of PI receptors in the heart; this stimulation then activates cyclic adenosine monophosphate (cyclic AMP) and facilitates release of calcium from the sarcoplasmic reticulum. Epinephrine and norepinephrine are the paradigms of drugs that have the capability of "whipping a dead heart." Both of these drugs increase myocardial contractility, heart rate, systemic vascular resistance, left-ventricular filling pressure, the frequency of supraventricular and ventricular arrhythmias, and infarct size.89 Similar effects are generally observed with dopamine in doses higher than 6,ug/kg/min. '0 These drugs will increase infarct size in experimental preparations Isoproterenol is the most arrhythmogenic of this group and can compromise arterial pressure because of its potent 12 effects.3 In contrast, low doses of dopamine (2-4,ug/kg/ min) or ofthe synthetic compound dobutamine can incease cardiac output with only a minimal effect on myocardial oxygen demand Dobutamine is the most cardioselective of the inotropic catecholamines. Clinical studies have demonstrated that the drug reduces both preload (left-ventricularfilling pressure) and afterload (systemic vascular resistance) with minimal anrhythmogenicity. The inotropic catecholamines have been used primarily in the setting of acute low cardiac output states. In hypotensive patients who have low systemic vascular resistances, the vasoconstrictive effects of norepinephrine and of high-dose dopamine may be useful adjuncts to therapy. Therapy for this group of patients is often complicated by other serious medical problems, such as sepsis, acute respiratory distress syndromes, and bleeding abnormalities that require monitoring of oxygen delivery and consumption in order to optimize treatment. Patients with acute cardiac failure caused by global or regional contractile abnormalities usually present with increased left ventricular filling pressure and systemic vascular resistance. Dobutamine is very effective in most of these patients. There has been recent interest in the use of intermittent infusions of dobutamine in patients with chronic heart failure;16'17 and this has been accompanied by speculation that the drug might have a conditioning effect directly upon the heart. Another possible explanation for dobutamine's observed benefit to patients in heart failure is that the temporary drug-induced improvement in left ventricular function might result in withdrawal of some of the adverse compensatory mechanisms (e.g., increased alpha adrenergic tone and salt and water retention). This phenomenon would be similar to the reduction in circulating toxins following dialysis that grants a brief respite to the kidney patient. Bipyridines. Amrinone is the first of a new group of inotropic drugs to be approved by the United States Food and Drug Administration. Initial reports about its mechanism of action and its potential side effects have been the subject of considerable debate in the literature. These controversies have stemmed in part from some confusion between results obtained with the intravenous form of the drug and those obtained with the oral form; this last was withdrawn voluntarily by the manufacturer because of frequent side effects (especially gastrointestinal distress and thrombocytopenia). Amrinone (5-amino-3,4'-bipyridine-6(lH)- one) is a bipyridine guanide that inhibits subfraction 3 phosphodiesterase and therefore increases cyclic AMP.23 It also directly increases uptake of extracellular calcium, which is the hallmark of all inotropic drugs. In patients, amrinone's effects on cardiac output, left-ventricular filling pressure, and systemic vascular resistance are similar to those of dobutamine.24 Amrinone has several 342 Pharmacologic Therapy for Congestive Cardiomyopathy Vol. 14, No. 4, December, 1987
3 potentially beneficial properties, including minimal chronotropic and arrhythmogenic effects, and the ability to reduce myocardial oxygen consumption in patients with ischemic cardiomyopathies; so it may be particularly useful in cases of coronary artery disease.2526 Elevation of liver enzymes has occurred after long-term administration of oral amrinone, but studies indicate this is not a problem in the short term.2' Unlike the oral form, intravenous amrinone appears to be very well tolerated. Reversible thrombocytopenia (platelet count <100,000/mm3) has been reported in approximately 2.4% of patients. If therapy is continued for more than 48 hours, daily platelet counts should be obtained and the dosage of the drug reduced if necessary. Well-designed clinical studies comparing intravenous amrinone to other available therapies should be performed before the drug can be recommended for heart failure in acute infarction. Vasodilator Therapy The normal physiologic role of the baroreceptors is to monitor and regulate the pressure-andvolume status of the circulation. When baroreceptors in the atria, ventricles, carotids, and aorta are stretched, afferent signals are transmitted via the glossopharyngeal and vagus nerves to the central nervous system, which then suppresses the output of vasoconstrictive hormones. In patients with congestive heart failure, however, these normal controls are disrupted, and there is a rise in the levels of renin, angiotensin, aldosterone, norepinephrine, and arginine vasopressin. These agents then increase aortic impedance and salt and water reabsorption. Although peripheral vasoconstriction is partly offset by release of local prostaglandins, a dangerous cycle develops, characterized by low cardiac output and elevated systemic vascular resistance, this last causing further decreases in cardiac output. Vasodilators for the therapy of heart failure can be classified according to their sites of action on the peripheral vascular bed. Drugs with venodilating properties reduce venous return to the heart, lower pulmonary and systemic venous pressures, and decrease intracardiac volume, resulting in relief of congestive symptoms. Vasodilators that cause arteriolar relaxation can improve left ventricular function by reducing the load, which in turn decreases impedance to left ventricular emptying and improves cardiac output. Vasodilators that have been used forheart failure include nitrates, nitroprusside, hydralazine, phentolamine, and the angiotensin-converting enzyme inhibitors captopril and enalapril. These drugs often can be given together, and/or in combination with the inotropic drugs, for synergistic effect. Nitroglycerin and Nitrate. Nitroglycerin and other organic nitrates relax the smooth vascular muscle of the venous capacitance bed and to a lesser extent the smooth muscle of the larger arteries of the systemic resistance bed. Whether administered sublingually, orally, or intravenously, nitrates have a rapid onset of action. Reductions in pulmonary capillary wedge pressure and in right atrial pressure are among the hemodynamic effects of nitrates. In addition, most patients display modest declines in systemic and pulmonary arterial pressure, and in pulmonary vascular resistance.27 Cardiac output after administration of nitrates may vary in accordance with leftventricular filling pressure: Patients with normal or low left-ventricular filling pressure tend to have decreased cardiac output, while patients with elevated left-ventricular filling pressure tend to have inreased cardiac output. Systemic vascular resistance can also vary with left-ventricular filling pressure, but usually does not. In addition, nitrates confer beneficial hemodynamic effects on patients with mitral and aortic insufficiency (since regurgitant volumes decrase when left-ventricular filling pressures derease).28 Sodium Nitroprusside. Sodium nitroprusside is a rapid and potent vasodilator that relaxes both arteriolar and venous smooth muscle. The hemodynamic effects of nitroprusside include a significant reduction of systemic vascular resistance, an increase in cardiac output, and a decrease in systemic and pulmonary venous pressure. Systemic and pulmonary arterial pressures tend to decrease, while heart rate is usually unchanged unless left-ventricular filling pressure is low, in which case reflex tachycardia might occur In addition to these actions of benefit to patients with heart failure, sodium nitroprusside can give relief to patients with acute mitral regurgitation and-in higher doses-to those undergoing hypertensive crises. Hydralazine. Hydralazine is an arterial vasodilator that acts directly to cause smooth-muscle relaxation, primarily of the precapillary resistance vessels.3' It has very litfle effect on the venous Pharmacologic Therapy for Congestive Cardiomyopathy 343
4 capacitance bed. Characteristic hemodynamic effects of hydralazine are an increase in cardiac output and a fall in systemic vascular resistance. Arterial pressure either remains unchanged or drops slightly.32 Reflex tachycardia occurs frequently in patients with normal cardiac dimensions, but only rarely in the presence of heart failure. Pulmonary vascular resistance decreases in most patients, although the magnitude of decrease is much smaller than with agents that predominantly affect venous capacitance. Hydralazine, in combination with nitrates, has been found useful for the long-term management of patients with chronic heart failure. It also produces substantial hemodynamic and clinical benefits in patients with chronic mitral and aortic insufficiency, conferring marked increases in forward stroke volume and in cardiac output, and a concomitant decrease in regurgitant volume.33 Phentolamine. Phentolamine is an alpha adrenergic blocking agent with a prominent directrelaxing effect on vascular smooth muscle. The drug has mild intrinsic beta adrenergic stimulating properties. The hemodynamic effects are similarto those of sodium nitroprusside. Arterial pressure, systemic vascular resistance, pulmonary capillary wedge pressure, right atrial pressure, and pulmonary arterial pressure are generally decreased, while cardiac output is increased. In contrast to sodium nitroprusside, phentolamine tends to increase the heart rate. The effects of phentolamine on left ventricular function are influenced by the initial level of left-ventricular filling pressure. In patients with high filling pressures, cardiac output increases and left-ventricular filling pressure decreases, whereas in the presence of normal-baseline left-ventricular filling pressures, cardiac output usually is unchanged or slightly increased, even though left-ventricular filling pressure decreases. Angiotensin-Converting Enzyme Inhibitors. Captopril and enalapril are vasodilators that work by blocking the conversion of angiotensin I to angiotensin II, thereby decreasing the levels of both angiotensin II and aldosterone, and reducing vasoconstriction and fluid retention. In patients with heart failure, cardiac output increases and is accompanied by a decrease in right atrial and pulmonary capillary wedge pressures. Mean arterial pressure, systemic vascular resistance, and pulmonary artery pressures usually decline, while heart rate and pulmonary vascular resistance do not change. Recent studies suggest that these drugs improve prognosis in patients with chronic heart failure. CONCLUSION The last ten years have seen a promising increase in the number of pharmacologic agents available for the tatment of congestive heart failure. One hopes that the decade yet to come will produce drugs capable of improving both the length and quality of life for patients suffering fiom this condition, a condition that at present may be described as "end stage," short of cardiac transplantation. REFERENCES 1. Chatterjee K, Parmley WW. The role of vasodilator therapy in heart failure. Prog Cardiovasc Dis 1977; 19: Maroko PR, Kjekshus JK, Sobel BE, Watanabe T, Covell JW, Ross J, Jr., Braunwald E. Factors influencing infarct size following experimental coronary artery occlusion. Circulation 1971; 3: Shell WE, Sobel BE. Deleterious effects of increased heart rate on infarct size in the conscious dog. Am J Cardiol 1973; 31: Shell WE, Sobel BE. Protection of jeopardized ischemic myocardium by reduction of ventricular afterload. N Engl J Med 1974; 291: Packer M, Medina N, Yushak M. Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure. Circulation 1984; 70: Bigger JT, Weld FM, Rotinitzky LM, Ferrick KJ. Is digitalis treatment harmful in the year after acute myocardial infarction? Circulation 1981; 64(Suppl IV): Moss AJ, Davis HT, Conrad DL, DeCamilla SJ, Odoroff CL. Digitalis-associated cardiac mortality after myocardial infarction? Circulation 1981; 64: Mueller H, Ayres SM, Gregory JJ, et al. Hemodynamics, coronary blood flow and myocardial metabolism in coronary shock response to L-norepinephrine and isoproterenol. J Clin Invest 1970; 49: Goldstein RA, Passamani ER, Roberts R. A comparison of digoxin and dobutamine in patients with acute infarction and cardiac failure. N Engl J Med 1980; 303: Smith TW, Haber E. Digitalis. N Engl J Med 1973; 289: Dodek A, Kassebaum DG, Bristow JD. Pulmonary edema in coronary artery disease without cardiomegaly: Paradox of the stiff heart. N Engl J Med 1972; 286: Pharmacologic Therapy for Congestive Cardiomyopathy Vol. 14, No. 4, December, 1987
5 12. Dougherty AH, Naccarelli GV, Gray EL, Hicks CH, Goldstein RA. Congestive heart failure with normal systolic function. Am J Cardiol 1984; 54: Allwood MJ, Cobbold AF, Gingburg J. Peripheral vascular effects of noradrenaline, isopropyl noradrenaline and dopamine. Br Med Bull 1963; 19: Gilman AC, Goodman LS, Gilman A (eds). The phamracological basis of therapeutics. New York, Macmillan, 1980; p Leier CV, Heban PT, Huss P. Comparative systemic and regional hemodynamic effects of dopamine and dobutamine in patients with cardiomyopathic heart failure. Circulation 1978; 58: Goldberg LI. Dopamine: Clinical uses of an endogenous catecholamine. N Engl J Med 1974; Goldberg LI, Hsuh Y, Resenekov L. Newer catecholamines for treatment of heart failure and shock: An update on dopamine and a first look at dobutamine. Prog Cardiovasc Dis 1977; 19: Leier CV, Huss P, Lewis RP, et al. Drug-induced conditioning in congestive heart failure. Circulation 1982; 65: Applefeld MM, Newman KA, Grove WR, Sutton FJ, Roffman DS, Reed WP, Linberg SE. Intermittent, continuous outpatient dobutamine infusion in the management of congestive heart failure. Am J Cardiol 1983; 51: Goldstein RA. When to use amrinone for the failing heart. Cardio 1986; 3: Goldstein RA. Clinical effects of intravenous amrinone in patients with congestive heart failure. Circulation; (Suppl III): Franciosa JA. Effectiveness of long-term vasodilator administration in the treatment of chronic left ventricular failure. Prog Cardiovasc Dis 1982; 14: Alousi AA, Farah AE, Lesher GY, Opalka CJ. Cardiotonic activity of amrinone. Circ Res 1979; 45: Klein NA, Siskind SJ, Frishman WH. Hemodynamic comparison of intravenous amrinone and dobutamine in patients with congestive heart failure. Am J Cardiol 1981; 48: Benotti JR, Grossman W, Braunwald E. Carabello BA. Effects of amrinone on myocardial energy metabolism and hemodynamics in patients with severe congestive heart failure due to coronary artery disease. Circulation 1980; 62: Naccarelli GV, Gray EL, Dougherty AH, Hanna JE, Goldstein RA. Amrinone: Acute electrophysiologic and hemodynamic effects in patients with congestive heart failure. Am J Cardiol 1984; 54: Chatterjee K, et al. Long-term outpatient vasodilator therapy of chronic congestive heart failure. Am J Med 1978; 65: Sniderman, et al. Response of the LV to nitroglycerin in patients with and without mitral regurgitation. Br Heart J 1978; 36: Chatterjee K, Ports TA, Parmley WW. Nitroprusside: Its clinical pharmacology and application in acute heart failure, in Gould and Reddy (eds) Vasodilator Therapy for Cardiac Disorders. New York, Future Publishing FranciosaJA, Guiha NH, Limas CJ, etal. Improved left ventricular function during nitroprusside infusion in acute myocardial infarction. Lancet 1972; 1: Fries ED, Rose JC, Higgins TF, et al. The hemodynamic effects of hypotensive drugs in man: (Part IV) I -hydrazinopthalazine. Circulation 1953; 8: Chatterjee K, Ports T, Brundage B, et al. Oral hydralazine in chronic heart failure: Sustained beneficial hemodynamic effects. Ann Intern Med 1980; 92: Greenberg BH, Massie BM. Beneficial effects of afterload reduction therapy in patients with congestive heart failure and moderate aortic stenosis. Circulation 1981; 62: Pharmacologic Therapy for Congestive Cardiomyopathy 345
Heart Failure (HF) Treatment
Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and
More informationDrugs Used in Heart Failure. Assistant Prof. Dr. Najlaa Saadi PhD pharmacology Faculty of Pharmacy University of Philadelphia
Drugs Used in Heart Failure Assistant Prof. Dr. Najlaa Saadi PhD pharmacology Faculty of Pharmacy University of Philadelphia Heart Failure Heart failure (HF), occurs when cardiac output is inadequate to
More informationFAILURE IN PATIENTS WITH MYOCARDIAL INFARCTION
Br. J. clin. Pharmac. (1982), 14, 187S-19lS BENEFICIAL EFFECTS OF CAPTOPRIL IN LEFT VENTRICULAR FAILURE IN PATIENTS WITH MYOCARDIAL INFARCTION J.P. BOUNHOURE, J.G. KAYANAKIS, J.M. FAUVEL & J. PUEL Departments
More informationAntihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Antihypertensive Agents Part-2 Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Agents that block production or action of angiotensin Angiotensin-converting
More informationLab Period: Name: Physiology Chapter 14 Blood Flow and Blood Pressure, Plus Fun Review Study Guide
Lab Period: Name: Physiology Chapter 14 Blood Flow and Blood Pressure, Plus Fun Review Study Guide Main Idea: The function of the circulatory system is to maintain adequate blood flow to all tissues. Clinical
More informationCardiac Drugs: Chapter 9 Worksheet Cardiac Agents. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate.
Complete the following. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate. 2. drugs affect the force of contraction and can be either positive or negative. 3.
More informationMedical Treatment for acute Decompensated Heart Failure. Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011
Medical Treatment for acute Decompensated Heart Failure Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011 2010 HFSA guidelines for ADHF 2009 focused update of the 2005 American College
More informationChapter 10. Learning Objectives. Learning Objectives 9/11/2012. Congestive Heart Failure
Chapter 10 Congestive Heart Failure Learning Objectives Explain concept of polypharmacy in treatment of congestive heart failure Explain function of diuretics Learning Objectives Discuss drugs used for
More informationHEART FAILURE PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
HEART FAILURE PHARMACOLOGY University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 LEARNING OBJECTIVES Understand the effects of heart failure in the body
More informationΔακτυλίτιδα και Ινότροπα Φάρμακα στην Καρδιακή Ανεπάρκεια. Ι.Κανονίδης
Δακτυλίτιδα και Ινότροπα Φάρμακα στην Καρδιακή Ανεπάρκεια Ι.Κανονίδης Cardiac Glycosides Chronic Congestive Heart Failure DIGOXIN Na-K ATPase Na + K + Na-Ca Exchange Na + Ca ++ Ca ++ K + Na + Myofilaments
More information1. Antihypertensive agents 2. Vasodilators & treatment of angina 3. Drugs used in heart failure 4. Drugs used in arrhythmias
1. Antihypertensive agents 2. Vasodilators & treatment of angina 3. Drugs used in heart failure 4. Drugs used in arrhythmias Only need to know drugs discussed in class At the end of this section you should
More informationHeart Failure. Subjective SOB (shortness of breath) Peripheral edema. Orthopnea (2-3 pillows) PND (paroxysmal nocturnal dyspnea)
Pharmacology I. Definitions A. Heart Failure (HF) Heart Failure Ezra Levy, Pharm.D. HF Results when one or both ventricles are unable to pump sufficient blood to meet the body s needs There are 2 types
More informationCardiovascular Physiology. Heart Physiology. Introduction. The heart. Electrophysiology of the heart
Cardiovascular Physiology Heart Physiology Introduction The cardiovascular system consists of the heart and two vascular systems, the systemic and pulmonary circulations. The heart pumps blood through
More informationStaging and Treating Patients with Heart Failure Henry Green, III, DVM, DACVIM Purdue University West Lafayette, IN
Staging and Treating Patients with Heart Failure Henry Green, III, DVM, DACVIM Purdue University West Lafayette, IN There are many different diseases that can cause signs of congestive heart failure(chf)
More information(D) (E) (F) 6. The extrasystolic beat would produce (A) increased pulse pressure because contractility. is increased. increased
Review Test 1. A 53-year-old woman is found, by arteriography, to have 5% narrowing of her left renal artery. What is the expected change in blood flow through the stenotic artery? Decrease to 1 2 Decrease
More informationIntroduction. Invasive Hemodynamic Monitoring. Determinants of Cardiovascular Function. Cardiovascular System. Hemodynamic Monitoring
Introduction Invasive Hemodynamic Monitoring Audis Bethea, Pharm.D. Assistant Professor Therapeutics IV January 21, 2004 Hemodynamic monitoring is necessary to assess and manage shock Information obtained
More informationHeart Failure. Dr. Alia Shatanawi
Heart Failure Dr. Alia Shatanawi Left systolic dysfunction secondary to coronary artery disease is the most common cause, account to 70% of all cases. Heart Failure Heart is unable to pump sufficient blood
More informationMedical Management of Acute Heart Failure
Critical Care Medicine and Trauma Medical Management of Acute Heart Failure Mary O. Gray, MD, FAHA Associate Professor of Medicine University of California, San Francisco Staff Cardiologist and Training
More informationDefinition of Congestive Heart Failure
Heart Failure Definition of Congestive Heart Failure A clinical syndrome of signs & symptoms resulting from the heart s inability to supply adequate tissue perfusion. CHF Epidemiology Affects 4.7 million
More informationCardiovascular Physiology
Cardiovascular Physiology Introduction The cardiovascular system consists of the heart and two vascular systems, the systemic and pulmonary circulations. The heart pumps blood through two vascular systems
More informationThe Treatment Targets in Acute Decompensated Heart Failure
SUCCESS WITH HEART FAILURE The Treatment Targets in Acute Decompensated Heart Failure Gregg C. Fonarow, MD The Ahmanson-UCLA Cardiomyopathy Center, Division of Cardiology, UCLA School of Medicine, Los
More informationNothing to Disclose. Severe Pulmonary Hypertension
Severe Ronald Pearl, MD, PhD Professor and Chair Department of Anesthesiology Stanford University Rpearl@stanford.edu Nothing to Disclose 65 year old female Elective knee surgery NYHA Class 3 Aortic stenosis
More informationVeins. VENOUS RETURN = PRELOAD = End Diastolic Volume= Blood returning to heart per cardiac cycle (EDV) or per minute (Venous Return)
Veins Venous system transports blood back to heart (VENOUS RETURN) Capillaries drain into venules Venules converge to form small veins that exit organs Smaller veins merge to form larger vessels Veins
More informationWhat would be the response of the sympathetic system to this patient s decrease in arterial pressure?
CASE 51 A 62-year-old man undergoes surgery to correct a herniated disc in his spine. The patient is thought to have an uncomplicated surgery until he complains of extreme abdominal distention and pain
More informationPre-discussion questions
Amanda Bartlett, PA-C Dustin Bartlett, PA-C Andrea Applegate, PA-C Leslie Yearta Brown, NP CHF Round Table Discussion Objectives ANDREA- Discuss the definition and different categories of CHF DUSTIN- Define
More informationBIPN100 F15 Human Physiol I (Kristan) Lecture 14 Cardiovascular control mechanisms p. 1
BIPN100 F15 Human Physiol I (Kristan) Lecture 14 Cardiovascular control mechanisms p. 1 Terms you should understand: hemorrhage, intrinsic and extrinsic mechanisms, anoxia, myocardial contractility, residual
More informationHeart Failure. Acute. Plasma [NE] (pg/ml) 24 Hours. Chronic
Heart Failure Heart failure is the inability of the heart to deliver sufficient blood to the tissues to ensure adequate oxygen supply. Clinically it is characterized by signs of volume overload or symptoms
More informationHaemodynamic effects of a new inotropic agent (dobutamine) in chronic cardiac failure
British Heart journal, 1975, 37, 629-634. Haemodynamic effects of a new inotropic agent (dobutamine) in chronic cardiac failure Jonas Beregovich, Christian Bianchi, Ralph D'Angelo, Ruth Diaz, and Shirley
More informationWRITER TRISTAN WALKER TABLE OF CONTENTS. The Basics of cardiac pharmacology 2007
WRITER TRISTAN WALKER TABLE OF CONTENTS 1. WHAT ARE THE MAJOR CLASSES OF CARDIAC DRUGS?...2 2. HOW DO THEY WORK?...3 3. CONSIDERATIONS FOR THE PEDIATRIC PATIENT...7 4. SUMMARY TABLE...10 REFERENCES...14
More informationCardiovascular System B L O O D V E S S E L S 2
Cardiovascular System B L O O D V E S S E L S 2 Blood Pressure Main factors influencing blood pressure: Cardiac output (CO) Peripheral resistance (PR) Blood volume Peripheral resistance is a major factor
More informationM2 TEACHING UNDERSTANDING PHARMACOLOGY
M2 TEACHING UNDERSTANDING PHARMACOLOGY USING CVS SYSTEM AS AN EXAMPLE NIGEL FONG 2 JAN 2014 TODAY S OBJECTIVE Pharmacology often seems like an endless list of mechanisms and side effects to memorize. To
More informationDrug Therapy of Heart Failure. Munir Gharaibeh, MD, PhD, MHPE Faculty of Medicine, The University of Jordan November, 2014
Drug Therapy of Heart Failure Munir Gharaibeh, MD, PhD, MHPE Faculty of Medicine, The University of Jordan November, 2014 Drug Therapy of Heart Failure Definition of Heart Failure Causes Classifications
More informationDIAGNOSIS AND MANAGEMENT OF ACUTE HEART FAILURE
DIAGNOSIS AND MANAGEMENT OF ACUTE HEART FAILURE Mefri Yanni, MD Bagian Kardiologi dan Kedokteran Vaskular RS.DR.M.Djamil Padang The 3rd Symcard Padang, Mei 2013 Outline Diagnosis Diagnosis Treatment options
More informationReview of Cardiac Mechanics & Pharmacology 10/23/2016. Brent Dunworth, CRNA, MSN, MBA 1. Learning Objectives
Brent Dunworth, CRNA, MSN, MBA Associate Director of Advanced Practice Division Chief, Nurse Anesthesia Vanderbilt University Medical Center Nashville, Tennessee Learning Objectives Review the principles
More informationHYPERTENSION: Sustained elevation of arterial blood pressure above normal o Systolic 140 mm Hg and/or o Diastolic 90 mm Hg
Lecture 39 Anti-Hypertensives B-Rod BLOOD PRESSURE: Systolic / Diastolic NORMAL: 120/80 Systolic = measure of pressure as heart is beating Diastolic = measure of pressure while heart is at rest between
More informationCirculation. Blood Pressure and Antihypertensive Medications. Venous Return. Arterial flow. Regulation of Cardiac Output.
Circulation Blood Pressure and Antihypertensive Medications Two systems Pulmonary (low pressure) Systemic (high pressure) Aorta 120 mmhg Large arteries 110 mmhg Arterioles 40 mmhg Arteriolar capillaries
More informationBlood Pressure Regulation. Slides 9-12 Mean Arterial Pressure (MAP) = 1/3 systolic pressure + 2/3 diastolic pressure
Sheet physiology(18) Sunday 24-November Blood Pressure Regulation Slides 9-12 Mean Arterial Pressure (MAP) = 1/3 systolic pressure + 2/3 diastolic pressure MAP= Diastolic Pressure+1/3 Pulse Pressure CO=MAP/TPR
More informationMedical Management of Acutely Decompensated Heart Failure. William T. Abraham, MD Director, Division of Cardiovascular Medicine
Medical Management of Acutely Decompensated Heart Failure William T. Abraham, MD Director, Division of Cardiovascular Medicine Orlando, Florida October 7-9, 2011 Goals of Acute Heart Failure Therapy Alleviate
More informationTowards a Greater Understanding of Cardiac Medications Foundational Cardiac Concepts That Must Be Understood:
Towards a Greater Understanding of Cardiac Medications Foundational Cardiac Concepts That Must Be Understood: Cardiac Output (CO) CO=SVxHR (stroke volume x heart rate) Cardiac output: The amount of blood
More informationBlood Pressure Regulation. Faisal I. Mohammed, MD,PhD
Blood Pressure Regulation Faisal I. Mohammed, MD,PhD 1 Objectives Outline the short term and long term regulators of BP Know how baroreceptors and chemoreceptors work Know function of the atrial reflex.
More informationStructure and organization of blood vessels
The cardiovascular system Structure of the heart The cardiac cycle Structure and organization of blood vessels What is the cardiovascular system? The heart is a double pump heart arteries arterioles veins
More informationCLINICAL AND HAEMODYNAMIC EFFECTS OF MILRINONE IN THE TREATMENT OF LOW CARDIAC OUTPUT AFTER CARDIAC SURGERY
British Journal of Anaesthesia 1991; 67: 585-590 CLINICAL AND HAEMODYNAMIC EFFECTS OF MILRINONE IN THE TREATMENT OF LOW CARDIAC OUTPUT AFTER CARDIAC SURGERY E. M. WRIGHT AND K. M. SHERRY SUMMARY We have
More informationHypovolemic Shock: Regulation of Blood Pressure
CARDIOVASCULAR PHYSIOLOGY 81 Case 15 Hypovolemic Shock: Regulation of Blood Pressure Mavis Byrne is a 78-year-old widow who was brought to the emergency room one evening by her sister. Early in the day,
More informationCLINICAL AND HAEMODYNAMIC RESPONSES TO CAPTOPRIL AND HYDRALAZINE IN CHRONIC CONGESTIVE HEART
Br. J. clin. Pharmac. (1982), 14, 217S-222S CLINICAL AND HAEMODYNAMIC RESPONSES TO CAPTOPRIL AND HYDRALAZINE IN CHRONIC CONGESTE HEART FAILURE: THE IMPORTANCE OF PRELOAD REDUCTION DESMOND J. FITZGERALD,I
More informationTreatment of Congestive Heart Failure
Treatment of Congestive Heart Failure Öner Süzer www.onersuzer.com osuzer@istanbul.edu.tr Last update: 13.01.2009 1 2 1 Congestive Heart Failure I Congestive heart failure (CHF) is a major contributor
More informationHeart failure. Failure? blood supply insufficient for body needs. CHF = congestive heart failure. increased blood volume, interstitial fluid
Failure? blood supply insufficient for body needs CHF = congestive heart failure increased blood volume, interstitial fluid Underlying causes/risk factors Ischemic heart disease (CAD) 70% hypertension
More informationHemodynamic Effects of Nitroprusside and Hydralazine in Experimental Cardiac Tamponade
Hemodynamic Effects of Nitroprusside and Hydralazine in Experimental Cardiac Tamponade NOBLE 0. FOWLER, M.D., MARJORIE GABEL, AND JOHN C. HOLMES, M.D. SUMMARY Cardiac tamponade is associated with decreased
More informationANTI - ARRHYTHMIC DRUGS
ANTI - ARRHYTHMIC DRUGS CARDIAC ACTION POTENTIAL K Out Balance Ca in/k out Na in K Out GENERATION OF ARRHYTHMIAS Four mechanisms of arrhythmia generation; Increased normal automaticity Abnormal automaticity
More informationCase year old female nursing home resident with a hx CAD, PUD, recent hip fracture Transferred to ED with decreased mental status BP in ED 80/50
Case 1 65 year old female nursing home resident with a hx CAD, PUD, recent hip fracture Transferred to ED with decreased mental status BP in ED 80/50 Case 1 65 year old female nursing home resident with
More informationMcHenry Western Lake County EMS System Paramedic, EMT-B and PHRN Optional Continuing Education 2018 #12 Understanding Preload and Afterload
McHenry Western Lake County EMS System Paramedic, EMT-B and PHRN Optional Continuing Education 2018 #12 Understanding Preload and Afterload Cardiac output (CO) represents the volume of blood that is delivered
More informationSwans and Pressors. Vanderbilt Surgery Summer School Ricky Shinall
Swans and Pressors Vanderbilt Surgery Summer School Ricky Shinall Shock, Swans, Pressors in 15 minutes 4 Reasons for Shock 4 Swan numbers to know 7 Pressors =15 things to know 4 Reasons for Shock Not enough
More informationSwans and Pressors. Vanderbilt Surgery Summer School Ricky Shinall
Swans and Pressors Vanderbilt Surgery Summer School Ricky Shinall SHOCK Hypotension SHOCK Hypotension SHOCK=Reduction of systemic tissue perfusion, resulting in decreased oxygen delivery to the tissues.
More informationMyocardial Infarction: Left Ventricular Failure
CARDIOVASCULAR PHYSIOLOGY 93 Case 17 Myocardial Infarction: Left Ventricular Failure Marvin Zimmerman is a 52-year-old construction manager who is significantly overweight. Despite his physician's repeated
More informationHypertensives Emergency and Urgency
Hypertensives Emergency and Urgency Budi Yuli Setianto Cardiology Divisision Department of Internal Medicine Faculty of Medicine UGM Sardjito Hospital Yogyakarta Background USA: Hypertension is 30% of
More informationThe Cardiovascular System
The Cardiovascular System The Cardiovascular System A closed system of the heart and blood vessels The heart pumps blood Blood vessels allow blood to circulate to all parts of the body The function of
More informationImages have been removed from the PowerPoint slides in this handout due to copyright restrictions.
Heart Failure Heart Failure Introduction and History AHA 2015 Statistics About 6 million Americans 870,000 new cases each year 1 in 9 deaths related to HF Almost 1 million hospitalizations each year (cost
More informationCopyright 2011, 2007 by Mosby, Inc., an affiliate of Elsevier Inc. Normal Cardiac Anatomy
Mosby,, an affiliate of Elsevier Normal Cardiac Anatomy Impaired cardiac pumping Results in vasoconstriction & fluid retention Characterized by ventricular dysfunction, reduced exercise tolerance, diminished
More informationIn Vivo Animal Models of Heart Disease. Why Animal Models of Disease? Timothy A Hacker, PhD Department of Medicine University of Wisconsin-Madison
In Vivo Animal Models of Heart Disease Timothy A Hacker, PhD Department of Medicine University of Wisconsin-Madison Why Animal Models of Disease? Heart Failure (HF) Leading cause of morbidity and mortality
More informationCardiovascular Nursing Practice: A Comprehensive Resource Manual and Study Guide for Clinical Nurses 2 nd Edition
Cardiovascular Nursing Practice: A Comprehensive Resource Manual and Study Guide for Clinical Nurses 2 nd Edition Table of Contents Volume 1 Chapter 1: Cardiovascular Anatomy and Physiology Basic Cardiac
More informationImpedance Cardiography (ICG) Application of ICG in Intensive Care and Emergency
Impedance Cardiography (ICG) Application of ICG in Intensive Care and Emergency Aim of haemodynamic monitoring in ICU and ED Detection and therapy of insufficient organ perfusion Answers to common cardiovascular
More informationWeeks 1-3:Cardiovascular
Weeks 1-3:Cardiovascular Cardiac Output The total volume of blood ejected from the ventricles in one minute is known as the cardiac output. Heart Rate (HR) X Stroke Volume (SV) = Cardiac Output Normal
More informationKeynote Address II Managing Acute Heart Failure: What Can We Do to Improve Outcomes?
Keynote Address II Managing Acute Heart Failure: What Can We Do to Improve Outcomes? 24 th Annual San Diego Heart Failure Symposium June 1-2, 2018 La Jolla, CA Barry Greenberg, MD Distinguished Professor
More informationPercutaneous Mechanical Circulatory Support for Cardiogenic Shock. 24 th Annual San Diego Heart Failure Symposium Ryan R Reeves, MD FSCAI
Percutaneous Mechanical Circulatory Support for Cardiogenic Shock 24 th Annual San Diego Heart Failure Symposium Ryan R Reeves, MD FSCAI The Need for Circulatory Support Basic Pathophysiologic Problems:
More information7/21/2017. Learning Objectives. Current Cardiovascular Pharmacology. Epinephrine. Cardiotonic Agents. Epinephrine. Epinephrine. Arthur Jones, EdD, RRT
Learning Objectives Current Cardiovascular Pharmacology Arthur Jones, EdD, RRT Explain the actions, effects, indications, adverse effects, & precautions for agents from the following drug categories Cardiotonic
More informationChapter 10 Worksheet Blood Pressure and Antithrombotic Agents
Complete the following. 1. A layer of cells lines each vessel in the vascular system. This layer is a passive barrier that keeps cells and proteins from going into tissues; it also contains substances
More informationIntroductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs
Introductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs Blood Pressure Normal = sys
More informationAntihypertensive drugs SUMMARY Made by: Lama Shatat
Antihypertensive drugs SUMMARY Made by: Lama Shatat Diuretic Thiazide diuretics The loop diuretics Potassium-sparing Diuretics *Hydrochlorothiazide *Chlorthalidone *Furosemide *Torsemide *Bumetanide Aldosterone
More informationHeart Failure Update John Coyle, M.D.
Heart Failure Update 2011 John Coyle, M.D. Causes of Heart Failure Anderson,B.Am Heart J 1993;126:632-40 It It is now well-established that at least one-half of the patients presenting with symptoms and
More informationPharmacology - Problem Drill 11: Vasoactive Agents
Pharmacology - Problem Drill 11: Vasoactive Agents Question No. 1 of 10 1. Vascular smooth muscle contraction is triggered by a rise in. Question #01 (A) Luminal calcium (B) Extracellular calcium (C) Intracellular
More informationMechanism: 1- waterretention from the last part of the nephron which increases blood volume, venous return EDV, stroke volume and cardiac output.
Blood pressure regulators: 1- Short term regulation:nervous system Occurs Within secondsof the change in BP (they are short term because after a while (2-3 days) they adapt/reset the new blood pressure
More informationChapter 9. Learning Objectives. Learning Objectives 9/11/2012. Cardiac Arrhythmias. Define electrical therapy
Chapter 9 Cardiac Arrhythmias Learning Objectives Define electrical therapy Explain why electrical therapy is preferred initial therapy over drug administration for cardiac arrest and some arrhythmias
More informationIntravenous Infusions
Intravenous Infusions 1) An IV insulin infusion can be used for patients: a) with out of control diabetes b) with DKA (Diabetic Ketoacidosis) c) after a heart attack 2) Hyperglycemia is an adaptive response
More informationMEDICAL MANAGEMENT OF PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION
MEDICAL MANAGEMENT OF PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION FRANCIS X. CELIS, D.O. OPSO FALL CONFERENCE PORTLAND, OR 16 SEPTEMBER 2017 OVERVIEW What are the ACC/AHA Stages of HF? What
More informationTitrating Critical Care Medications
Titrating Critical Care Medications Chad Johnson, MSN (NED), RN, CNCC(C), CNS-cc Clinical Nurse Specialist: Critical Care and Neurosurgical Services E-mail: johnsoc@tbh.net Copyright 2017 1 Learning Objectives
More informationAnaesthesia. Update in. An Introduction to Cardiovascular Physiology. James Rogers Correspondence
Update in Anaesthesia Originally published in Update in Anaesthesia, edition 10 (1999) An Introduction to Cardiovascular Physiology Correspondence Email: James.Rogers@nbt.nhs.uk INTRODUCTION The cardiovascular
More informationIntravenous Inotropic Support an Overview
Intravenous Inotropic Support an Overview Shaul Atar, MD Western Galilee Medical Center, Nahariya Affiliated with the Faculty of Medicine of the Galilee, Safed, Israel INOTROPES in Acute HF (not vasopressors)
More informationREGULATION OF CARDIOVASCULAR SYSTEM
REGULATION OF CARDIOVASCULAR SYSTEM Jonas Addae Medical Sciences, UWI REGULATION OF CARDIOVASCULAR SYSTEM Intrinsic Coupling of cardiac and vascular functions - Autoregulation of vessel diameter Extrinsic
More informationCARDIOGENIC SHOCK. Antonio Pesenti. Università degli Studi di Milano Bicocca Azienda Ospedaliera San Gerardo Monza (MI)
CARDIOGENIC SHOCK Antonio Pesenti Università degli Studi di Milano Bicocca Azienda Ospedaliera San Gerardo Monza (MI) Primary myocardial dysfunction resulting in the inability of the heart to mantain an
More informationCardiovascular Physiology and Pharmacology
Cardiovascular Physiology and Pharmacology Peter Paal Perioperative Medicine, Barts Heart Centre St. Bartholomew s Hospital, Barts Healt NHS Queen Mary University of London and Department of Anaesthesiology
More informationPeripartum Cardiomyopathy. Lavanya Rai Manipal
Peripartum Cardiomyopathy Lavanya Rai Manipal Definition - PPCM - Dilated cardiomyopathy of unknown cause resulting in cardiac failure that occurs in the peripartum period in women without any preexisting
More informationA practical approach to critical care of cardiac disease
A practical approach to critical care of cardiac disease J.H. Robben, DVM, dipl. ECVIM-CA, Intensivist Head of the Intensive Care Unit Department of Clinical Sciences of Companion Animals Faculty of Veterinary
More informationEffects of Cilostazol in Patients With Bradycardiac Atrial Fibrillation
J Cardiol 2001 ; 37: 27 33 Effects of Cilostazol in Patients With Bradycardiac Atrial Fibrillation 1 2 1 Masato Kouki KISHIDA, MD WATANABE, MD Abstract Objectives. Cilostazol, an antithrombotic agent,
More informationProtocol Identifier Subject Identifier Visit Description. [Y] Yes [N] No. [Y] Yes [N] N. If Yes, admission date and time: Day Month Year
PAST MEDICAL HISTORY Has the subject had a prior episode of heart failure? o Does the subject have a prior history of exposure to cardiotoxins, such as anthracyclines? URGENT HEART FAILURE VISIT Did heart
More informationProperties of Pressure
OBJECTIVES Overview Relationship between pressure and flow Understand the differences between series and parallel circuits Cardiac output and its distribution Cardiac function Control of blood pressure
More informationBIOH122 Session 6 Vascular Regulation
BIOH122 Session 6 Vascular Regulation To complete this worksheet, select: Module: Distribution Title: Vascular Regulation Introduction 1. a. How do Mean Arterial Blood Pressure (MABP) and Systemic Vascular
More informationIndex of subjects. effect on ventricular tachycardia 30 treatment with 101, 116 boosterpump 80 Brockenbrough phenomenon 55, 125
145 Index of subjects A accessory pathways 3 amiodarone 4, 5, 6, 23, 30, 97, 102 angina pectoris 4, 24, 1l0, 137, 139, 140 angulation, of cavity 73, 74 aorta aortic flow velocity 2 aortic insufficiency
More informationBlood pressure. Formation of the blood pressure: Blood pressure. Formation of the blood pressure 5/1/12
Blood pressure Blood pressure Dr Badri Paudel www.badripaudel.com Ø Blood pressure means the force exerted by the blood against the vessel wall Ø ( or the force exerted by the blood against any unit area
More informationDOWNLOAD PDF ABC OF HEART FAILURE
Chapter 1 : The ABCs of managing systolic heart failure: Past, present, and future Heart failure is a multisystem disorder which is characterised by abnormalities of cardiac, skeletal muscle, and renal
More informationComparison of Dopamine and Dobutamine Follaking CoronG Artery Bypass Grafting
Comparison of Dopamine and Dobutamine Follaking CoronG Artery Bypass Grafting Neal W. Salomon, M.D., John R. Plachetka, Pharm.D., and Jack G. Copeland, M.D. ABSTRACT A prospective, randomized comparison
More informationBlood pressure control Contin. Reflex Mechanisms. Dr. Hiwa Shafiq
Blood pressure control Contin. Reflex Mechanisms Dr. Hiwa Shafiq 17-12-2018 A. Baroreceptor reflexes Baroreceptors (stretch receptors) located in the walls of several large systemic arteries( specially
More informationPHENTOLAMINE MESYLATE INJECTION SANDOZ STANDARD 5 mg/ ml THERAPEUTIC CLASSIFICATION Alpha-adrenoreceptor Blocker
PACKAGE INSERT Pr PHENTOLAMINE MESYLATE INJECTION SANDOZ STANDARD 5 mg/ ml THERAPEUTIC CLASSIFICATION Alpha-adrenoreceptor Blocker ACTIONS AND CLINICAL PHARMACOLOGY Phentolamine produces an alpha-adrenergic
More informationImproving Transition of Care in Congestive Heart Failure. Mark J. Gloth, DO, MBA. Vice President, Chief Medical Officer HCR ManorCare
Improving Transition of Care in Congestive Heart Failure Mark J. Gloth, DO, MBA. Vice President, Chief Medical Officer HCR ManorCare Heart Failure Fastest growing clinical cardiac disease in the United
More informationDRUG CLASSES BETA-ADRENOCEPTOR ANTAGONISTS (BETA-BLOCKERS)
DRUG CLASSES BETA-ADRENOCEPTOR ANTAGONISTS (BETA-BLOCKERS) Beta-blockers have been widely used in the management of angina, certain tachyarrhythmias and heart failure, as well as in hypertension. Examples
More informationBlood Pressure Regulation -1
CVS Physiology Lecture 18 Blood Pressure Regulation -1 Please study the previous sheet before studying this one, even if the first part in this sheet is revision. In the previous lecture we were talking
More informationInnovation therapy in Heart Failure
Innovation therapy in Heart Failure P. Laothavorn September 2015 Topics of discussion Basic Knowledge about heart failure Standard therapy New emerging therapy References: standard Therapy in Heart Failure
More informationHYPERTENSION IN EMERGENCY MEDICINE Michael Jay Bresler, M.D., FACEP
HYPERTENSION IN EMERGENCY MEDICINE Michael Jay Bresler, M.D., FACEP What is normal blood pressure? Prehypertension 130-139/80-90 Compared with normal BP Double the risk for developing hypertension. Lifestyle
More informationHOW LOW CAN YOU GO? HYPOTENSION AND THE ANESTHETIZED PATIENT.
HOW LOW CAN YOU GO? HYPOTENSION AND THE ANESTHETIZED PATIENT. Donna M. Sisak, CVT, LVT, VTS (Anesthesia/Analgesia) Seattle Veterinary Specialists Kirkland, WA dsisak@svsvet.com THE ANESTHETIZED PATIENT
More informationDisclosures. Objectives 10/11/17. Short Term Mechanical Circulatory Support for Advanced Cardiogenic Shock. I have no disclosures to report
Short Term Mechanical Circulatory Support for Advanced Cardiogenic Shock Christopher K. Gordon MSN, ACNP-BC Disclosures I have no disclosures to report 1. Pathophysiology 2. Epidemiology 3. Assessment
More informationChapter (9) Calcium Antagonists
Chapter (9) Calcium Antagonists (CALCIUM CHANNEL BLOCKERS) Classification Mechanism of Anti-ischemic Actions Indications Drug Interaction with Verapamil Contraindications Adverse Effects Treatment of Drug
More informationTreatment of T Angina reatment of By Ali Alalawi
Treatment of Angina By Ali Alalawi Determinants of Oxygen Demand Need to improve ratio of: Coronary blood flow / cardiac work Or Cardiac O2 Supply / Cardiac Requirement Coronary Circulation vs Other Circulation
More information